NIH-supported trials to test synthetic antibody treatments
Researchers have launched two clinical trials to test whether monoclonal (laboratory-made) antibodies can safely prevent SARS-CoV-2 infection or symptoms in healthy adults, the National Institutes of Health announced yesterday.
One trial will evaluate a Regeneron Pharmaceuticals investigational treatment in about 2,000 asymptomatic adults who are household contacts of people infected with SARS-CoV-2.
The other will assess an Eli Lilly and Company investigational treatment in up to 2,400 people who reside or work in skilled nursing or assisted living facilities.
Related News Articles
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…